About

KBI Biopharma, Inc. KBI Biopharma, a JSR Life Sciences company, is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com. Selexis SA Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com About KBI BioPharma, Inc. KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com. About KBI Biopharma KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com. KBI Biopharma, a JSR Life Sciences company, is your expert CDMO partner for complex biologics. From development through manufacturing, trust us to solve your challenges, so you can focus on what matters most - the cures. With expertise that accelerates your path to clinic and market through advanced platforms for mammalian and microbial production, deep CMC and analytical capabilities, and end-to-end CLD-to-vial services, KBI biopharma helps you bring even your most challenging molecules to clinic and market with confidence. With platforms that accelerate your path to clinic and market, KBI Biopharma brings deep expertise across mammalian and microbial production, CMC strategy, and advanced analytics. Our end-to-end services, from cell line development to drug product, are built to help you confidently advance even the most complex molecules. Whether it’s mammalian cell line development powered by Selexis®, high-yield PUREcoli™ microbial strains, or robust manufacturing solutions, our integrated approach simplifies your journey from concept to commercialization. You’ll also benefit from PROGRAMview™, our innovative digital platform that brings a new standard of transparency to CDMO partnerships, giving your team real-time access to data, smarter decision-making, and milestone-driven execution. With dual operations in the U.S. and Europe and over 170 molecules supported, we deliver global regulatory insight and solutions tailored to your unique program needs. KBI Biopharma is the CDMO of choice for complex biologics and expert analytics, helping life science companies accelerate the development and manufacture of innovative therapies and vaccines. With roots in analytical services and deep technical expertise in mammalian and microbial programs, KBI provides process development, analytical, and cGMP manufacturing services across the drug development lifecycle. KBI’s technologies support more than 250 drug candidates in preclinical and clinical development and 15 marketed products. KBI partners with customers to solve challenges, drive breakthroughs, and advance programs to market – serving customers from six locations across the US and Europe. Learn more at www.kbibiopharma.com.